KODIAK SCIENCES INC. (KOD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 52.77M USD | Liabilities, Current |
| Cash and equivalents | 125.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $52.77M | $125.90M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $49.57M | $169.53M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $45.53M | $209.86M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $42.43M | $72.04M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $31.01M | $104.17M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $30.88M | $138.85M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $25.57M | $168.07M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $24.06M | $197.86M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $21.20M | $219.22M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $24.86M | $245.92M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $41.73M | $285.51M | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | (m) | $70.77M | $345.67M | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | (m) | $74.24M | $378.67M | $0.00 | (m) | (m) | (m) |
| 2023-03-31 | (m) | $68.94M | $316.62M | $104.58M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $52.50M | $190.43M | $288.50M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $65.60M | $178.41M | $358.98M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $69.83M | $172.69M | $425.18M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $76.33M | $671.73M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $64.68M | $731.51M | $0.00 | (m) | (m) | (m) |
| 2021-09-30 | (m) | $54.40M | $799.25M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $41.02M | $880.87M | $0.00 | (m) | (m) | (m) |
| 2021-03-31 | (m) | $35.06M | $920.46M | $8.52M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $31.42M | $944.40M | $24.58M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $22.50M | $291.58M | $88.86M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $18.77M | $269.84M | $147.30M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $13.83M | $226.46M | $195.40M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $11.71M | $211.80M | $124.68M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $7.30M | $37.03M | $23.57M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $6.21M | $44.97M | $23.13M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $4.77M | $57.22M | $23.85M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.83M | $88.25M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $5.38M | $11.59M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $17.64M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $22.81M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $9.16M | $1.40M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $6.39M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $9.62M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |